- Home
- IBOC vs PTGX Comparison
IBOC vs PTGX Comparison
Compare IBOC & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBOC
- PTGX
- Stock Information
- Founded
- IBOC 1966
- PTGX 2006
- Country
- IBOC United States
- PTGX United States
- Employees
- IBOC N/A
- PTGX N/A
- Industry
- IBOC Major Banks
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- IBOC Finance
- PTGX Health Care
- Exchange
- IBOC Nasdaq
- PTGX Nasdaq
- Market Cap
- IBOC 4.2B
- PTGX 5.0B
- IPO Year
- IBOC N/A
- PTGX 2016
- Fundamental
- Price
- IBOC $66.23
- PTGX $85.30
- Analyst Decision
- IBOC
- PTGX Strong Buy
- Analyst Count
- IBOC 0
- PTGX 9
- Target Price
- IBOC N/A
- PTGX $86.44
- AVG Volume (30 Days)
- IBOC 233.4K
- PTGX 912.3K
- Earning Date
- IBOC 11-06-2025
- PTGX 11-06-2025
- Dividend Yield
- IBOC 2.12%
- PTGX N/A
- EPS Growth
- IBOC 5.13
- PTGX N/A
- EPS
- IBOC 6.76
- PTGX 0.72
- Revenue
- IBOC $821,716,000.00
- PTGX $209,217,000.00
- Revenue This Year
- IBOC N/A
- PTGX N/A
- Revenue Next Year
- IBOC N/A
- PTGX $140.23
- P/E Ratio
- IBOC $9.64
- PTGX $117.38
- Revenue Growth
- IBOC 2.80
- PTGX N/A
- 52 Week Low
- IBOC $54.11
- PTGX $33.31
- 52 Week High
- IBOC $76.91
- PTGX $93.25
- Technical
- Relative Strength Index (RSI)
- IBOC 45.81
- PTGX 66.16
- Support Level
- IBOC $64.37
- PTGX $76.70
- Resistance Level
- IBOC $67.05
- PTGX $86.90
- Average True Range (ATR)
- IBOC 1.63
- PTGX 3.20
- MACD
- IBOC -0.09
- PTGX 0.30
- Stochastic Oscillator
- IBOC 35.36
- PTGX 83.71
About IBOC International Bancshares Corporation
International Bancshares Corp is a multibank financial holding company. The company provides commercial and retail banking services in Texas and Oklahoma. The services provided by the bank include checking, savings, bank cards, lending, insurance, mortgage, investments, and other services.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.